A digital health company which focuses on clinical risk prevention has appointed an AI specialist to develop future technologies.
Rinicare, based in Manchester, announced Miguel Mendao was taking over as chief technology and data officer.
Managing director, Anthony Holmes, said: “Miguel is joining Rinicare at a really exciting time, with the first trial deployment of one of our clinical solutions, STABILITY UO, on the horizon.
“Our ethos is to deliver effective, AI-driven technology which genuinely solves problems for clinicians and makes patients safer, so it is fantastic to have someone with Miguel’s AI expertise joining us.”
Rinicare’s technology portfolio is focused on clinical risk prediction to improve patient safety and is designed to deliver support, as well as improving patient care.
Miguel has has worked on building AI teams and product offerings for the EMEA and APAC markets.
He holds a PhD in Artificial Intelligence (Machine Learning & Control Architectures), from the University of Kent, and worked as Post Doctoral Research Associate in Artificial Immune Systems at the University of York.
Rinicare is a Manchester-based clinician-led digital health company focused on improving clinical risk prediction and, therefore, patient safety. Our growing range of solutions helps build confidence in a patient’s near-term clinical condition, supporting discharge decisions and informing earlier clinical interventions to help prevent adverse events